Poolbeg Pharma plc (LON: POLB), a clinical-stage biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced its unaudited interim results for the six months to 30 June 2024.
Highlights, Business Update & Outlook
| ● | Cash balance of £10.1 million as at 30 June 2024, demonstrating continued prudent financial management |
| ● | Independent research has confirmed a potential market opportunity of c.US$10 billion for POLB 001 as an orally delivered preventative therapy for cancer immunotherapy-induced Cytokine Release Syndrome (CRS)1 |
| ● | Robust data package in place for POLB 001 – efficacy demonstrated in reducing cancer immunotherapy-induced CRS in an in vivo animal model, strengthening and facilitating the expansion of patent applications |
| ● | US Patent Office granted the Company’s Immunomodulator II patent application covering a class of drugs, including POLB 001, to treat or prevent hypercytokinemia (cytokine storm) induced in any disease indication |
| ● | Engagement continues with potential partners in relation to POLB 001 |
| ● | Exclusive 12-month option agreement signed for tPTX, a novel, topical, muco-adherent treatment for oral ulcers in patients suffering from Behçet’s Disease, with FDA Fast Track Designation, Orphan Drug Designation and potential 505(b)(2) approval pathway in the US |
